Risk assessment on use of Lactobacillus rhamnosus (LGG) as an ingredient in infant formula and baby foods (II) by Rimstad, Espen et al.
Norwegian Scientific Committee for Food Safety 
Risk assessment on use of Lactobacillus rhamnosus (LGG) 
as an ingredient in infant formula and baby foods (II) 
The Norwegian Scientific Committee for Food Safety 
Panel on biological hazards 
& 
Panel on nutrition, dietetic products, novel food and allergy 
June 2007 
1
VKM Report 2007: 38
Norwegian Scientific Committee for Food Safety 
Contents  
I- Abstract................................................................................................................................... 3 
II- Sammendrag.......................................................................................................................... 5 
III- Background .......................................................................................................................... 7 
IV- Terms of Reference.............................................................................................................. 8 
V- Opinion.................................................................................................................................. 9 
VI- Evaluation of reports and scientific papers........................................................................ 13 
VII- Answers to the questions.................................................................................................. 13 
VIII- Appendix I....................................................................................................................... 16 
XI- References.......................................................................................................................... 31 
X- Scientific Panel members.................................................................................................... 32 
2
Norwegian Scientific Committee for Food Safety 
I- Abstract 
On 10. March 2006 , The Norwegian Food Safety Authority (Mattilsynet) decided 
that, on the basis of VKM’s previous risk assessment (2005), Nutramigen 1 with 
Lactobacillus rhamnosus GG (LGG) could not be marketed in Norway as medical 
foods for infants (0-4 months). In addition, The Norwegian Food Safety Authority 
(Mattilsynet) decided (08. November 2006) to withdraw permission for marketing of 
Nutramigen 2 with LGG, which is a milk supplement for infants aged between 4 and 6 
months, with cow’s milk and soy protein allergy. On 13. December 2006, Mead 
Johnson Nutritionals appealed against this decision from The Norwegian Food Safety 
Authority (Mattilsynet). The Norwegian Food Safety Authority forwarded the appeal 
from the companies, asked the VKM Panel on biological hazards and the VKM Panel 
on nutrition, dietetic products, novel food and allergy, for a new risk assessment 
including the new data provided in the appeal. 
 LGG is one of the most studied probiotic strains. Lactic acid produced by LGG in the 
human gut results in a decrease in faecal pH, which in turn inhibits colonisation by 
potentially pathogenic bacteria. Short-term beneficial effects from administration of 
LGG to infants and young children with infectious diarrhoea have been reported in a 
number of studies, but a prophylactic effect on diarrhoea has not been documented. 
Furthermore, whilst some studies have reported a prophylactic, or even a curative, 
effect of LGG on atopic eczema in young children, more recent studies do not report 
such effects. Some even suggest an increased incidence of allergic sensitization in 
children receiving LGG supplemented formula at an early age. There are no 
published data that demonstrate long-term clinical benefits of infant formula 
supplemented with LGG for children between 4 months and 3 years, although no 
immediate deleterious effects of LGG have been found. Possible long-term effects of 
LGG on intestinal colonisation, and its effects on long-term gastrointestinal and 
immune functions, are not known.  
LGG, as an ingredient in infant formula and baby foods, is intended for daily use in 
the target group, and not for short-term, specific treatment. Furthermore, the targeted 
consumer group includes children below the age of twelve months. These two 
aspects demand particular consideration with regard to the unknown effects of long-
term treatment with large doses of live bacteria on the ecology of the microbiota of 
the gastrointestinal tract and on the immune system. Neither of these systems is fully 
matured in infants and small children, and therefore may be particularly susceptible. 
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There is no documented prophylactic effect of LGG on any disease in children.  The 
effect of treatment with LGG-supplemented formula in small children is questionable, 
except for a documented short-term effect on infectious diarrhoea. Panel on 
Biological Hazards and Panel on nutrition, dietetic products, novel food and allergy at 
the Norwegian Scientific Committee for Food Safety find that the data available are 
not sufficient to support the suggested beneficial effects, or the safety, of LGG in 
infant formula and baby foods for children aged between 4 months and 3 years, 
when the products are intended for daily use. 
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II- Sammendrag 
Basert på VKMs tidligere risikovurdering fra 2005, bestemte Mattilsynet 10. mars 
2006 at Nutramigen 1 med LGG ikke kunne markedsføres som næringsmiddel til 
spesielle medisinske formål (0-4 måneder) i Norge. I tillegg trakk Mattilsynet tilbake 
tillatelsen (08. november, 2006) til å markedsføre Nutramigen 2 med LGG, som er en 
melkeerstatning for spedbarn mellom fire og seks måneder som er allergiske mot 
kumelk og soyaproteiner. Den 13. desember 2006 Mead Johnson Nutritionals på 
vedtaket fra Mattilsynet. Mattilsynet videresendte klagen fra selskapene og ba VKMs 
faggrupper for hygiene og smittestoffer samt ernæring, dietetiske produkter, ny mat 
og allergi om å foreta en ny risikovurdering basert på nye data som er lagt frem i 
forbindelse med klagen. 
Lactobacillus rhamnosus GG (LGG) er en av de mest studerte probiotiske 
bakteriestammene. Produksjon av melkesyre fra LGG reduserer pH i feces og 
kolonisering av potensielt patogene mikrober kan derved forhindres.  Flere studier 
kan vise til en kortsiktig gunstig effekt av LGG på infeksiøs diaré hos sped- og 
småbarn, men en forebyggende effekt på diaré er ikke dokumentert. Det er studier 
som rapporterer en forebyggende og også behandlende effekt av LGG ved atopisk 
eksem hos sped- og småbarn.  Nyere studier kan ikke reprodusere en slik effekt og 
enkelte nye studier viser til og med en øket allergisk sensibilisering hos spedbarn 
som får LGG-tilskudd. Det er ikke publisert data som støtter en lang tids gunstig 
klinisk effekt av morsmelkerstatninger med LGG for barn mellom 4 måneder og 3 år 
selv om ingen umiddelbare uheldige bivirkninger er funnet. Mulige langtids effekter 
på kolonisering i tarm og virkningen av slik kolonisering på tarmens funksjon og 
immunologisk funksjon generelt er ukjent. LGG som tilsats i morsmelkerstatninger og 
barnemat er ment for daglig bruk i målgruppen og ikke for spesifikk korttids 
behandling. Videre inkluderer målgruppen små barn <1 år. Dette er fakta som maner 
til spesiell aktsomhet når det gjelder ukjente virkninger av langtids behandling med 
store doser levende bakterier på økologien i tarmen og på immunsystemet.  Verken 
tarmens mikrobiota eller immunsystemet generelt er ferdig modnet hos sped- og 
småbarn opp til 2–3 år. Virkningen av LGG supplementering i morsmelkerstatninger 
og småbarnmat er usikker bortsett fra en dokumentert korttids effekt på diaré. VKMs 
faggrupper for hygiene og smittestoffer samt ernæring, dietetiske produkter, ny mat 
og allergi konkluderer med at de foreliggende data vedrørende effekt og sikkerhet 
ikke er tilstrekkelige til å anbefale bruk av LGG i morsmelkerstatninger eller 
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småbarnmat til barn mellom 4 måneder og 3 år så lenge produktene er beregnet for 
daglig bruk.   
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III- Background 
In 2003, The Norwegian Food Safety Authority (Mattilsynet) was asked by Nutri 
Konsult Täby (Finland) to permit the marketing of infant formula that had been 
supplemented with Lactobacillus rhamnosus (LGG) at a concentration of 108 CFU/g 
formula. 
In March 2004, The Norwegian Scientific Committee for Food Safety (VKM) was 
asked by The Norwegian Food Safety Authority to address this issue (00/1956/touse 
and 2000/1956/gyomj). In response, an ad hoc Working Group of experts was 
appointed with the mandate to draft a risk assessment regarding the use of LGG in 
infant formula and baby foods. In February 2005, the VKM Panel on nutrition, dietetic 
products, novel food and allergy performed a risk assessment, which concluded that:  
 
The long-term effects on the immune function (immune defence, allergy, 
autoimmunity) of the gut, and systemically, when LGG is given to small children is 
unknown.  
The long-term effects of a heavy, artificial, single-species bacterial load on the 
newborn infant intestine is unknown. 
Since there is no documented prophylactic effect of LGG on any diseases in children, 
there is currently no medical indication for supplementing milk substitutes or 
children’s food with LGG. 
 
On 29.03.05, Mead Johnson Nutritionals commented on this risk assessment, 
provided some additional data, and asked for re-evaluation of the recommendations 
that had resulted from the risk assessment. The VKM panel on nutrition, dietetic 
products, novel food and allergy discussed the comments from the companies and 
made some modifications to the conclusion in a corrigendum (28.06.05). The risk 
assessment, including corrigendum, is available at www.vkm.no. 
 
Based on this risk assessment, on 10. March 2006, The Norwegian Food Safety 
Authority decided that Nutramigen 1 with LGG could not be marketed as medical 
nutrition for infants (0-4 months) in Norway. In addition, The Norwegian Food Safety 
Authority decided (08. November, 2006) to withdraw permission for marketing of 
Nutramigen 2 with LGG, which is a milk supplement for infants aged between 4 and 6 
months, with cow’s milk and soy protein allergy. On 13. December 2006, Mead 
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Johnson Nutritionals appealed against the decision from The Norwegian Food Safety 
Authority. The Norwegian Food Safety Authority forwarded the appeal from the 
company, including new reports and scientific articles, to the VKM for further 
evaluation. 
Based on the overall content of the appeal, The Norwegian Food Safety Authority 
asked the VKM Panel on biological hazards and the VKM Panel on nutrition, dietetic 
products, novel food and allergy, for a new risk assessment including the new data 
provided in the appeal. In response, an ad hoc Working Group of experts was 
appointed with the mandate to draft the appeal from the Norwegian Food Safety 
Authority. 
 
IV- Terms of Reference1
In collaboration with the Norwegian Scientific Committee for Food Safety (VKM), a mandate 
was prepared for the group reviewing the appeal. 
The Norwegian Food Safety Authority requests VKM to address the following questions: 
1. Has there been published, in the period since the preparation of the report ‘Risk 
assessment on use of Lactobacillus rhamnosus (LGG) as an ingredient in infant formula 
and baby foods’, including the associated corrigendum, up until today, any articles or 
reports that provide a basis for a re-evaluation of the above named risk assessment’s 
conclusion, with respect to: 
1.1. Possible long-term effects on the immune system generally, and intestinal immune 
function in particular, from use of LGG in infant formula that are classified as 
medicinal foods for babies and infants over 4 months. 
                                                 
1  
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1.2. Possible long-term effects on intestinal colonisation from the use of LGG in infant 
formula classified as medicinal foods for babies and infants over 4 months. 
1.3. LGG’s lack of prophylactic effect. 
2. Has there been observed, in infant formula that are classified as medicinal foods for 
babies and infants over 4 months, any beneficial effects from the use of products with 
added LGG, in comparison with similar products without added LGG? 
3. If VKM should consider that there is sufficient scientific documentation, based upon 
generally accepted data, which indicates that infant formula with added LGG, classified 
as medicinal foods for babies and infants over 4 months, have individual or various 
beneficial effects, will VKM, after a complete assessment (including an assessment of the 
safety and possible side effects associated with use of LGG in this group of consumers), 
recommend the use of infant formula products that are classified as medicinal nutriments, 
with added LGG, for babies and infants over 4 months? 
 
V- Opinion 
One of our major concerns regarding supplementation of infant food with LGG, is the 
possible long-term effects from any factors that affect the establishment of intestinal 
microbiota in early infancy. The microbiota of the intestine are not fully established 
until after 2 years of age. Thus factors that influence the composition of the 
microbiota at an early stage might permanently affect the further development of the 
ecosystem. This is demonstrated by studies on mode of delivery and intestinal 
microbiota, which are outlined below. Caesarean delivery affects the composition of 
early microbiota, since infants that are delivered by a caesarean section do not have 
any input of microbes from the birth canal, and differences in intestinal microbiota 
have been reported in children delivered by a caesarean, compared with children 
delivered vaginally. Of more interest is the finding that children delivered by 
caesarean do not apparently attain  over time the same flora as the babies that have 
been delivered vaginally (Bennet and Nord 1987). Differences in the composition of 
intestinal micobiota are still evident in children delivered by caesarean when they 
reach 6 months of age (Gronlund et al. 1999), and even at 7 years of age (Salminen 
et al. 2004). 
 
While there is some limited information regarding the effects of single-species 
bacterial load on the short-term composition of the newborn infant intestinal 
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microbiota, there is no information at all on the effects of supplementing the diets of 
infants and small children with LGG over a prolonged period of time on the long-term 
composition of their intestinal microbiota. Such information is crucial. 
 
In small children (<6 months) infant formula may represent their only food, and be a 
substantial part of their diet up to 1 year. If this infant formula is supplemented with a 
probiotic bacterial culture, then this culture will be present in large numbers in all, or 
most, of the food that they consume. This is an entirely different situation to the 
consumption of a probiotic yoghurt by an adult as a small part of their total diet. In 
comparing these circumstances it is obvious that the challenge to the resident flora is 
likely to be much greater in small children than in adults.  Additionally, the counter-
challenge from the resident flora is likely to be considerably less in small children 
than in adults, and this could allow greater proliferation of the given probiotic strain. 
 
Furthermore, there is little knowledge of the enzymatic properties of the single-
species bacterial load. Recent studies have shown that microbes have the ability to 
alter gene expression in enterocytes. There is, however, no available knowledge on 
how LGG alters gene expression in the enterocytes. These are factors that may have 
effects on the diversity of microbiota in the intestine, as well as other unwanted side 
effects. In vitro data presented by Yan et al., (Yan et al. 2007), showing that LGG 
may regulate intestinal epithelial cell survival and growth, strengthened our concerns 
about possible long-term effects of a dietary mono-bacterial supplement to the age-
groups in question. 
 
Several of the papers put forward show apparently favourable effects on some of the 
cytokines and immune markers studied. However, studies showing a favourable shift 
in one or two markers failed to convince us of the overall benefit of the 
supplementation, due to the well-known complexity of the immune system. This is 
illustrated by knowledge on allergic diseases, as outlined below. The immune 
response towards Th2 in allergic diseases is documented as being skewed, and this 
was the basis for the Th1/Th2 paradigm, in which it was believed that treatment or 
prophylaxis of allergic diseases could be obtained if the balance could be shifted 
towards an increase in Th1 responses. However, as autoimmune diseases are based 
on Th1 responses, this balance must be very delicate. Furthermore, a multitude of 
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different disease phenotypes exist, which are associated with different complex 
patterns of cytokines, and not even the allergic phenotypes are limited to Th2 types. 
Thus, a study that shows an increase in cytokines believed to be advantageous may 
be associated with an increase in less favourable cytokines, which may, or may not, 
be detected. Some studies have reported an increase in food allergy (Kalliomaki et 
al. 2003) and allergic sensitisation (Taylor et al. 2007) among children given LGG as 
part of clinical  trials on the effect of LGG on atopic eczema, and these have added to 
our concern that this may actually be the case.  
Increased insight into the fine-tuning of the immune system has recently been 
gained, and the crucial role of regulatory T-cells has been established. Rather than 
shifting the balance from Th2 to Th1, an independent down-regulation of the Th2 
responses may be needed in order to prevent allergy (and, correspondingly, a down-
regulation in Th1 responses may be needed in order to prevent autoimmune 
diseases). However, the characteristics of these regulatory T-cells still remain largely 
undefined (Woodfolk 2006).  
The fact is, that we presently do not have the scientific knowledge necessary to start 
manipulating the immune system in a predicable manner by administration of 
probiotics, and manipulation at an early age is of particular concern as the effects 
may be non-reversible. Our lack of knowledge necessitates the application of 
precautionary principles.   
 
Other comments: 
Most of the papers provided by Mead Johnson and Valio support the use of LGG for 
the treatment of diarrhoea. As was noted in our previous risk assessment, LGG may 
have some beneficial effects in the treatment of viral infectious diarrhoea in infants 
and young children, and may shorten the period of illness by 1 or 2 days. However, 
the claim that incorporation of LGG into infant formula and baby foods may assist in 
the prophylaxis of diarrhoea lacks supportive data. 
 
Furthermore, previous studies that suggested that LGG might have a moderately 
beneficial effect in the prevention of atopic eczema in some sub-populations of 
sensitized children, are not supported by data from a new study, although a probiotic 
supplement other than LGG was used in this study (Abrahamsson et al. 2007). 
Conflicting results have been obtained in studies on treatment of atopic eczema by 
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LGG administration.  Those studies which indicated a beneficial effect (Kalliomaki et 
al. 2001)(Viljanen et al. 2005)(Weston et al. 2005), have been contradicted by data 
obtained in more recent studies (Brouwer et al. 2006;Folster-Holst et al. 2006;Taylor 
et al. 2007). Moreover, there is some evidence that administration of probiotic 
bacteria to pregnant women, and to children via infant formula, may increase the 
degree of allergic sensitization in children with atopic eczema (Kalliomaki et al. 
2001;Kalliomaki et al. 2003;Taylor et al. 2007) 
 
In nutritional, as well as pharmaceutical, studies, the value of any claim is 
strengthened if the compound under study is administered in a similar format to the 
one intended for the market. With the exception of one study (Rautava et al. 2006), a 
general weakness in nearly all of the new clinical papers that have been provided by 
Mead Johnson and Valio, is that they have not used infant formula or baby foods in 
which LGG is an ingredient. The LGG-preparations used in these studies differ in 
composition from that of infant formula with LGG, and therefore any effect of matrix 
(infant formula and baby foods without LGG) is unknown.  
Of interest, however, is the finding of elevated levels of cow’s milk-specific IgA 
associated with Enfamil feeding. However, the results are inconsistent as the 
expected corresponding result for TGF-β2 was not observed (Rautava et al. 2006), 
and this strengthens our concerns about the unknown effects on the total immune 
system. Furthermore, the study results should be confirmed in other studies, and the 
long-term effect(s) of LGG still need to be elucidated 
 
The expert group, who performed the GRAS determination on request from Valio, Ltd 
and Mead Johnson, also did not confirm any beneficial effects of LGG with respect to 
allergic symptoms. Although many infants with impaired immune competence, heart 
defects, or central line requirements are probably not identified at birth, the expert 
group nevertheless suggested that the consumption of LGG is acceptable from birth 
onwards. Additionally, the expert group did not exclude translocation of LGG; this has 
previously been reported in 2 patients who received LGG and subsequently 
developed bacteraemia and sepsis, which was attributed to the LGG (Land et al. 
2005). The expert group suggested that “the powder containing Lactobacillus casei 
ssp. rhamnosus strain (LGG) manufactured by Valio Ltd., is generally recognised as 
safe (GRAS) by scientific procedure for use under the supervision of a physician as a 
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source of LGG in formula intended for term infants from time of birth”. In our opinion, 
by suggesting that product containing LGG is to be used under supervision of a 
physician, indicates that this product cannot be considered as food.      
 
Effects on growth and behaviour 
The number of individuals involved in published studies is often so low that it is not 
possible to draw any firm conclusions on infants/children as a population. Claims 
such as “Infants fed with LGG-enriched formulas are better than those fed with 
regular formula” are usually not substantiated by relevant facts. In general, infants 
receiving LGG had a slight, but not significant, increased tendency towards crying, 
vomiting, and loose stools. Possible mechanisms behind these slight differences are 
virtually unknown and deserve a more thorough investigation before LGG is 
introduced to the market in infant food. 
In summary, it can be concluded that:  
1. LGG has been widely studied and characterized in short-term trials. 
2. No immediate deleterious effects of LGG have been found. 
3. LGG seems to have some beneficial effects on infectious diarrhoea in infants 
and young children. 
4. Some studies indicate that early inclusion of LGG into the diet may provoke 
allergic sensitization. 
5. No scientific proof of a prophylactic effect on any disease is provided.    
6. Data on the possible beneficial effect of LGG on atopic eczema in infants and 
small children is conflicting, and the most recent studies conclude that it has 
no effect. 
7. Long-term effects on immune function in general, or of the gut in particular, 
when LGG is consumed on a daily basis is not known. 
 
VI- Evaluation of reports and scientific papers 
See Appendix I and Answers to the questions. 
 
VII- Answers to the questions  
The Norwegian Food Safety Authority requested VKM to address the following 
questions: 
1. Has there been published, in the period since the preparation of the report 
‘Risk assessment on use of Lactobacillus rhamnosus (LGG) as an ingredient in 
infant formula and baby foods’, and including the associated corrigendum, up 
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until today, any articles or reports that provide a basis for a re-evaluation of the 
above named risk assessment’s conclusion, with respect to: 
1.1. Possible long-term effects on the immune system generally, and 
intestinal immune function in particular, from use of LGG in infant formula 
products that are classified as medicinal nutriments for babies and infants 
over 4 months. 
Although several studies addressing the inclusion of LGG, or other probiotic 
bacteria, into children’s diets have been published between 2004 and today, none 
of these studies address the potential long-term effects of including LGG into the 
diet on the intestinal immune system or the immune system in general.  
Furthermore, in only one study has the LGG been administered as intended for 
the market, (i.e. in an infant formula), but this study also does not address long-
term effects on immunity.  Thus, our re-evaluation concludes that scientific 
knowledge on long-term effects of LGG on the intestinal and general immune 
system is still lacking. 
 
1.2. Possible long-term effects on intestinal colonisation from the use of 
LGG in infant formula products that are classified as medicinal nutriments 
for babies and infants over 4 months. 
The newest literature, from 2004 to date, does not provide information on the 
long-term effects on intestinal colonisation from the use of LGG in infant formula 
products for infants older than four months.  
 
1.3. LGG’s lack of prophylactic effect. 
Recently published reports do not substantiate the claim that LGG supplemented 
formula will have a prophylactic effect on any disease, including atopic eczema, 
allergic sensitization, or viral or antibiotic-associated diarrhoea. 
 
2. Has there been observed, in infant formula products that are classified 
as medicinal nutriments for babies and infants over 4 months, any 
beneficial effects from the use of the products with added LGG, in 
comparison with similar products without added LGG? 
No obvious beneficial effects of LGG-supplemented formula have been 
observed compared with formula not supplemented with LGG. Again it should 
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be noted that only one study gives information on the use of LGG-
supplemented formula. 
 
3. If VKM should consider that there is sufficient scientific documentation, 
based upon generally accepted data, which indicates that infant formula 
products with added LGG, that are classified as medicinal nutriments for 
babies and infants over 4 months, have individual or various beneficial 
effects, will VKM, after a complete assessment (including an assessment 
of the safety and possible side effects associated with use of LGG in this 
consumer group), recommend the use of infant formula products that 
are classified as medicinal nutriments, with added LGG, for babies and 
infants over 4 months? 
 
After complete assessment of the scientific documentation, including an 
assessment of safety and possible side effects associated with the daily use of 
LGG in this consumer group (consisting of children aged between four months 
and 2-3 years), VKM does not recommend the use of infant formula products 
that are classified as medicinal nutriments with added LGG, for infants over 
four months. 
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VIII- Appendix I 
Viljanen M, Savilahi E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, 
Tuure T, Kuitunen M.  (2005). Probiotics in the treatment of atopic 
eczema/dermatitis syndrome in infants: a double blind placebo controlled trial. Allergy 
60: 494-500. 
 
This is a double-blind, placebo-controlled study of 230 infants with AEDS, with or 
without CMA, and with or without IgE involvement.  The infants were randomised into 
three groups, one of which received LGG, one of which received a mix of LGG and 
other probiotic bacteria, and one of which received placebo. Administration was for 
four weeks following the first visit.  SCORAD was assessed at the first visit, after 4 
weeks, and at 8 weeks.  Skin treatment with emollients and 1% hydrocortisone was 
instituted at the first visit and all children were kept on a CM-free diet, with 
supplementation with an extensively hydrolysed whey formula. 
Symptoms of AEDS improved continuously, as indicated by decreasing SCORAD 
throughout the study period. No differences were detected in SCORAD decrease 
between the groups. However, a subgroup of infants with IgE-associated AEDS 
showed a significantly greater SCORAD decrease in the LGG group than in the mix 
or placebo group.  Faecal prevalence of probiotic strains was high in the treatment 
groups, indicating that the protocol was followed. 
Comments: The aim of this study was to investigate the effect of a 4-week treatment 
period with LGG on AEDS in infants.  An overall improvement in symptoms during 
the treatment period in all groups was detected, although a somewhat greater 
improvement in a subgroup of infants with IgE-associated AEDS receiving LGG 
supplementation was reported.  The study did not focus on safety and no side effects 
were reported. The treatment period was short, but considerable amounts of probiotic 
bacteria were administered to the infants in the treatment groups. 
 
 
Pohjavuori E, Viljanen M, Korpela R, Kuitunen M, Tittanen M, Vaarala O, 
Savilahti E. (2004).  Lactobacillus GG effect in increasing IFN-γ production in infants 
with cow’s milk allergy. J. Allergy Clin. Immunol. 114:131-6 
 
230 infants participated in a double-blind, placebo-controlled study as described in 
the previous publication.  This article reports experiments with in vitro stimulation of 
patient PBMC before and after the four-week treatment period with probiotic bacteria 
(protocol as described in the previous article).  The main result was an increase in 
IFN- γ production in the subgroup of infants with IgE-associated AEDS who received 
LGG, but not in those receiving a mix of probiotic bacteria or in the placebo group. 
LGG did not influence the IFN- γ level in non IgE-associated AEDS.  The increase 
corresponded with clinical improvement in the IgE-associated AEDS LGG group.  
The authors concluded that Lactobacillus strains might offer clinical benefits that are 
mediated by immunological mechanisms. 
Comments:  The article demonstrates that immunological changes may occur in a 
subgroup of infants whose diets are supplemented with LGG. There is no mention of 
side effects, but the study did not focus on safety.  The results are interesting, but 
perhaps unsurprising, as immunological effects of an oral supplement of a live 
bacterial strain were demonstrated.  The clinical benefits of this immunological 
phenomenon remain to be proven. 
 
 16
Norwegian Scientific Committee for Food Safety 
Viljanen M, Pohjavuori E, Haahtela T, Korpela R, Kuitunen M, Sarnesto A, 
Vaarala O, Savilahti E. (2005). Induction of inflammation as a possible mechanism 
of probiotic effect in atopic eczema-dermatitis syndrome. J. Allergy Clin. Immunol. 
115:1254-9. 
 
This is the same patient population as in the previous two articles. In this publication 
the effect of probiotics on infants’ intestinal immune systems was studied by 
measuring the systemic concentrations of cytokines (IL-2, IL-4, IL-6, IL 10, IFN γ,  
TNF α, TGF β1, TGF β2), inflammatory marker (CRP), soluble adhesion molecule (E-
selectin), and intercellular adhesion molecule (ICAM-1) both before and after LGG 
supplementation.  A slight, but significant, up-regulation of IL-6 and CRP was 
demonstrated in IgE-associated AEDS infants who received LGG for four weeks. The 
other two treatment groups did not exhibit these changes, indicating a competition 
between probiotic strains in the gut flora. The authors discussed the possibility that 
probiotics stimulate the intestinal immune system, inducing low-grade inflammation, 
which alleviates allergic symptoms. 
Comments: The study reports immunological changes in peripheral blood in a 
subgroup of infants with AEDS and suspected CMA. The changes corresponded with 
clinical improvement reported in another article (cited above).  There is no focus on 
safety, and no mention of side effects. The probiotics were administered to the 
infants over a relatively short time period, but in considerable doses. 
 
Laitinen K, Kalliomaki M, Poussa T, Lagstrøm H, Isolauri E. (2005). Evaluation of 
diet and growth in children with and without atopic eczema: follow up study from birth 
to 4 years. Br. J. Nutr. 94:565-74 
 
This study aimed to evaluate nutritional factors and their impact on AD in a cohort of 
children described previously (Kalliomaki et al. 2001) whose mothers had received 
LGG supplementation during pregnancy, and the children continued to receive LGG 
postnatally. The method used was a four-day food diary, and associations between 
foods and AD were investigated by logistic regression models.  It was concluded that 
retinol, Ca, and Zn, together with probiotics, reduced the risk of AD, whilst elevated 
intake of ascorbic acid increased the likelihood of AD. The authors concluded that 
perinatal administration of probiotics is safe as it did not influence the height, or the 
weight for height, of the children at 48 months, and that the combined effects of 
nutrients and probiotics should be considered in active prevention and management 
schemes for allergic diseases. 
Comments: This study does not provide any new knowledge on the effect of 
probiotics, and repeats that which has already been published on the same cohort by 
(Kalliomaki et al. 2001). The administration of LGG was considered safe as it did not 
influence the growth of the children, but no mention was made of effects on 
gastrointestinal immunity or of potential long-term effects of probiotics. 
 
Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. (1992). 
Enhancement of the circulating antibody secreting cell response in human diarrhea 
by a human Lactobacillus strain.  Pediatr. Res. 32:141-144. 
 
The authors report on the effect of LGG administered during an acute rotavirus 
infection, and seeks to elucidate the mechanisms behind the clinical effect on the 
diarrhoea.  LGG therapy was associated with a significant, non-specific humoral 
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response during the acute phase of the infection.  During convalescence the study 
group had a significantly higher IgA specific antibody-secreting cell response to 
rotavirus, indicating that LGG augmented the local immune defence.   
Comments: LGG and other probiotica seem to have a favourable effect on acute 
rotavirus diarrhoea. This means short-term use of the bacteria, which in many studies 
has proven to be safe, can be beneficial in particular circumstances. Our concerns 
are directed towards long-term effects and possible threats from prolonged, regular 
intake. 
 
Taylor A, Dunstan J, Prescott S. (2007). Probiotic supplementation for the first 6 
months of life fails to reduce the risk of atopic dermatitis and increases the risk of 
allergen sensitization in high-risk children: A randomized controlled trial.  J. Allergy 
Clin. Immunol. 119:184-9. 
 
This is an investigation of high-risk children receiving a Lactobacillus strain (other 
than LGG) or placebo for the first 6 months of life. No effect of the probiotic on the 
presence of AD was noted at 6 and 12 months. The rate of allergic sensitization was 
significantly higher at 12 months in the probiotic group than in the placebo group. The 
conclusion was that no effect on AD was noted, and thus the possible benefit of 
probiotics on AD is unclear.  
Comments:  The higher allergic sensitization rate, especially to cow’s milk in the 
probiotic group, must be considered seriously. This finding was also apparent from 
the previous studies by Kalliomaki et al., (Kalliomaki et al. 2001).  No side effects of 
the probiotic were noted, apart from the sensitization, but this study was not designed 
to investigate safety. 
 
Gawronska A, Dziechciarz, P, Horvath, A, Szajewska H. (2007). A randomized 
double-blind placebo-controlled trial of Lacobacillus GG for abdominal pain disorders 
in children. Aliment Pharmacol. Ther. 25: 177-184.  
In a randomised, placebo-controlled intervention trial, 104 children with abdominal 
pain, from 6-16 years, were randomised into two groups, one of which received LGG 
for 4 weeks, and the other placebo. Stratification was by initial diagnosis; either 
functional dyspepsia (n=20), irritable bowel syndrome (n=37), or functional abdominal 
pain (n=47). Treatment success was defined as no pain. In the IBS group, children 
who received LGG were more likely to experience treatment success (33% and 5%, 
treatment success among LGG and placebo-treated, respectively). In the children 
with functional dyspepsia or functional abdominal pain, there were no significant 
differences between the two groups. In the overall group there was an effect, 
primarily due to the children with IBS. Although the number of children with treatment 
success, (i.e. no pain), differed significantly between groups, there was no overall 
improvement in severity of pain. A number of other outcomes are also reported. 
Comments: A well-designed study, although the number of participants was low. 
Despite power calculations being performed before beginning the study, the inclusion 
of subgroups, resulted in n being smaller than had been estimated as required. The 
difference in treatment results between the groups may therefore be coincidental, 
due to the small groups and the different outcome measures. Focus should therefore 
be on the whole group; this does show larger number of responders in the treatment 
group, but the results are inconsistent as there was no discernible effect on pain 
severity. 
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Gueimonde M, Kalliomaki M, Isolauri E, Salminen S.  (2006). Probiotic 
intervention in neonates - will permanent colonization ensue? J. Pediatr. 
Gastroenterol. Nutr. 42: 604-606. 
In this study the effect of maternal consumption of LGG for 2-4 weeks before delivery 
on neonatal microbiota was investigated in a group of 53 newborns with a family 
history of atopic disease, with focus directed particularly towards Bifidobacteria 
species. No differences in the concentrations of specific bifidobacterial species were 
detected at the different time points investigated (mother, before and after birth; 
infant, 5 days and 3 weeks). However, significant differences in the concentrations of 
B. breve and B. adolescentis were detected between infants belonging to the placebo 
and LGG group, at 5 days, but not at 3 weeks. Additionally, there was a non-
significant trend towards increased diversity of species in the group of children whose 
mothers had taken LGG (1.22 versus 0.81). 
Comments: This paper lacks crucial information on many aspects. There is an 
absence of information on randomisation process, and on the characteristics of the 2 
groups. No effort has been directed towards optimising homogeneity between the 
groups (mode of delivery, feeding regimens, and gestational age are all factors that 
may influence microbiota, and should have been considered). The number of 
subjects in each group is small. As 6 different species were examined at 2 different 
age points for the infants alone, 2 out of 10 findings would be expected to be caused 
by random variation. The inconsistency over time for the 2 species that differed at 5 
days, suggests that these results are perhaps only random findings, rather than true 
differences. The various attempts to place the non-significant finding of diversity into 
context  (Tables 2 and 3 in the publication) seem neither relevant nor convincing. 
It is not clear why LGG was not also monitored, in order to determine the rate of LGG 
colonisation in the infant, and whether this was a factor that affected the microbiota. 
Conclusion: there may, or may not, be an effect of LGG administration to the mother 
on the microbiota in the child, but this paper is inconclusive. This is a poorly-designed 
study, and inadequately described, and the reported results could be chance 
findings. 
 
 
Folster-Holst R, Muller F, Schnopp N, Abeck D, Kreiselmaier I, Lenz T, von 
Ruden U, Schrezenmeir J, Christophers E, Weichenthal M. (2006). Prospective 
randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to 
severe atopic dermatitis. Br. J. Dermatol. 155:1256-61. 
 
In this study the effect of LGG supplementation for 8 weeks on 54 infants aged 1 to 
55 months with moderate to severe atopic eczema was examined in a randomised 
intervention trial. No significant differences on eczema were detected between the 
placebo and LGG treatment group during the treatment period, as evaluated by 
SCORAD, pruritus, sleeplessness, use of corticosteroids, and ECP levels in faeces. 
Among children with a positive test for IGE sensitization, there was a SCORAD 
reduction of 6.9 in the LGG treatment group, and of 8.6 in the placebo group.  
Comments: Randomisation may have been unfortunate in this trial, with more 
allergic children placed in the placebo group, (particularly subjects with food allergy 
and rhinitis). This was a very small study, and therefore may have lacked the power 
to show significant differences. However, none of the non-significant trends in the 
data provide support for an effect of LGG; indeed, if there is any trend, it is in the 
opposite direction. The study seems to have been generally well conducted, but 
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although bottom-line characteristics are described, more information on the 
randomisation procedure could have been provided (children were “allocated” to 
receive LGG or placebo, they do not seem to have been allocated to each centre, 
which would have been a serious flaw in the study, but this is not totally certain from 
the information given). The dosage used in this study is higher and for a longer 
duration than in the last 2 studies.  
 
 
Rautava S, Arvilommi H, Isolauri E. (2006). Specific probiotics in enhancing 
maturation of IgA responses in formula-fed infants. Pediatr Res. 60:221-224. 
 
In this study the infants were randomised to receive either infant formula with LGG 
(Enfamil), or, if weaned early, placebo. IgA secreting cells, cow’s milk specific IgA, 
sCD14, and TGF-β2 were measured in serum at 3, 7, and 12 months of age. There 
was a tendency towards higher levels of cow’s milk specific IgA among the Enfamil-
treated infants, as compared with the placebo group at all age points, and this was 
significantly so at 7 months. Additionally the Enfamil-treated infants had higher levels 
of sCD14, and this was significantly different at 12 months. The serum 
concentrations of TGF-β2 were similar between the two groups at 3 months, lower in 
the Enfamil-treated infants at 7 months, and higher in this group at 12 months, but 
none of the differences were significant. The total number of IgA secreting cells was 
higher in the Enfamil-treated infants at all age points, but not significantly so at any 
time point. 
Comments: The findings of higher levels of cow’s milk specific IgA associated with 
Enfamil, seem consistent. As the author points out, correspondingly elevated results 
would have been expected for TGF-β2, but this was not detected. There was also a 
significant difference in sCD14, although the change in concentrations seems minor. 
More information on the randomisation process should have been provided in order 
to explain why the number of subjects differs between the 2 groups before drop out. 
Furthermore, although it is claimed that intention to treat is followed, results on 
dropouts are not included. Were no blood tests available on the dropouts? It would 
also have been useful to have the analysis repeated, but with subjects that had 
developed CMA/CMPI excluded. Whilst the bottom-line finding of increased cow’s 
milk specific IgA in the LGG treated group seems convincing, the investigation should 
be repeated in a larger study sample. 
 
Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Holt PG. (1999). 
Development of allergen-specific T-cell memory in atopic and normal children. The 
Lancet, 353; 196-200.  
  
In this study allergen-specific T-cell responses were compared in 31 children divided 
into two groups. One group had no familial risk of atopy and also remained without 
such disease up to at least 2 years of age, whilst the other group consisted of infants 
with a familial risk of atopy, and who developed definite disease before the age of 2 
years. The children were selected from a prospective cohort study that started follow-
up at birth. The main finding is that the children who subsequently developed atopic 
diseases had lower allergen-specific responses of Th2 type in cord blood, than 
children who remained healthy and was demonstrated for IL-4, IL-6, IL-10, and IL-13. 
All children showed allergen-specific Th2 responses at birth, but in healthy children 
the responses were quickly down-regulated. Interferon gamma production was low in 
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both groups at birth but increased rapidly among the children who remained healthy. 
The authors proposed that the decreased capacity to produce high levels of 
interferon gamma was the reason for the persistent Th2 profile in cytokine patterns 
among the atopic children. In contrast to the general reduced capacity to produce 
interferon gamma, which is seen in all infants after birth and which is believed to be 
caused by inefficient co-stimulation of accessory cells, the decreased capacity in 
atopic individuals seems to be associated with an intrinsic defect in T-cells (shown in 
Fig 5 in the publication: Nearly no Interferon gamma production by CD4 T cells from 
atopic individuals). The authors believe that the period of infancy is critical; if the Th2 
inhibitory signal is absent, early expansion and maturation of Th2 memory cells may 
occur. 
Comments: A well-designed and important study that received considerable 
attention at publication.  
 
 
Viljanen M, Kuitunen M, Haahtela T, Juntunen-Backman K, Korpela R, Savilahti 
E. (2005). Probiotic effects on faecal inflammatory markers and on faecal IgA in food 
allergic atopic eczema/dermatitis syndrome infants. Pediatr. Allergy Immunol. 16: 65-
71. 
 
This complex study is divided into several sections.  
Children with AEDS and suspected CMA 
First, 203 children with AEDS and suspected CMA, aged 1-12 months, were 
randomised to receive 1 of 3 treatment options: LGG, MIX (LGG + L.rhamnosus  
LC705 +  B. breve +  P. freudenreichii), or placebo for 1 month.  However, curiously 
only 102 of the 203 participants had their samples analysed for the markers of 
interest. The children were also simultaneously put on an elimination diet, which 
means that reaching a conclusion by comparison of before and after values is 
complicated, and only differences between groups at individual time points can be 
considered. IgA values tended to be higher in the LGG and MIX group than in the 
placebo group after treatment. However, as the values in the placebo group were 
lower before treatment the authors adjusted the results for pre-treatment values. 
Following this adjustment, a non-significant tendency for higher faecal IgA 
concentrations in LGG and MIX group, compared with the placebo group, was 
detected. Corresponding adjustments for TNF-α, antitrypsin, and ECP demonstrated 
no differences between the groups. 
Children with CMA/CMPI. 
In the second section, CMA/CMPI was confirmed in 120 out of the 203 participating 
children, as based on DBPCFC-tests. However, only 67 of these had had their 
samples analysed. In comparing values before and after treatment (parallel to the 
previous section for all the participants), no significant differences in IgA, TNF-α, 
antitrypsin, and ECP were detected between the treatment groups.   
In comparing values both before and after challenges, significantly higher faecal IgA 
levels were detected after challenge (as compared with before challenge) in the LGG 
group, but not in the MIX group or in the placebo group. Comparison of IgA levels 
after cow’s milk challenge, adjusted for pre-treatment values, showed no significant 
differences between the treatment groups in IgA, TNF-α, antitrypsin, and ECP levels.   
Children with CMA/CMPI and IgE sensitization to any antigen  
27 out of the 102 children with adverse reactions to milk demonstrated signs of IgE-
sensitization and had their values measured. 
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Significantly higher IgA levels, lower TNF-α levels, and borderline significantly higher 
antitrypsin levels were reported for the LGG group, but not for the MIX group. ECP 
was higher in the LGG group, but this was not significant. 
Comments: In the last analysis the sample size was very low (n for each group was 
14, 14, and 9). As well as the increase in IgA and decrease in TNF-α in the LGG 
group, which are assumed to be beneficial alterations, there were increases in 
antitrypsin and a non-significant increase in ECP;  this is unexpected and increases 
the concern that these results may be random findings associated with the small 
sample size.  In the definition of cases in the last section it is puzzling that the 
authors chose to include all types of IgE sensitizations, rather than only to milk, which 
would have provided a well-defined group of CMA children. 
It is noteworthy that the findings differ considerably between the LGG and MIX 
treatment groups. What this could mean, and why this is not discussed in the 
publication, are subjects for speculation.  
 
Blumer N, Sel S, Virna S, Patrascan CC, Zimmermann S, Herz U, Renz H, Garn 
H. (2007). Perinatal maternal application of Lactobacillus rhamnosus GG suppresses 
allergic airway inflammation in mouse offspring. Clin Exp Allergy 37: 348-357. 
 
The authors studied the effects of a perinatal LGG supplementation in mice on the 
development of allergic disorders in their offspring. The authors concluded that LGG 
might exert beneficial effects on the development of experimental allergic asthma, 
when applied in a very early phase of life.  
Comments: The number of mice in the experiment was low. High variations in 
individual results were obtained for some tests, and therefore the standard deviations 
were high. It is not clear whether the results can be extrapolated to humans. 
 
Isolauri E, Joensuu J, Suomalainen H, Luomala M, and Vesikari T. (1995) 
Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by 
Lactobacillus casei GG. Vaccine 13: 310-312 
 
Effects of orally-administrated LGG in conjunction with live oral rotavirus vaccine 
were tested in 2-5 month-old infants. Infants who received LGG showed an increased 
responsiveness of rotavirus-specific IgM-secreting cells, as measured with an 
ELISPOT technique on day 8 after vaccination. Both IgM and IgA seroconversion 
were higher in infants receiving LGG, as compared with the placebo group. 
Comments: The authors did not study the duration of protection against rotavirus, 
and the IgM and IgA seroconversions against serogroups of rotavirus other than 
those used in the study were not measured. Concentrations of IgA and IgM in the 
intestinal mucus layer were not measured and studies on cellular immunity were not 
performed. 
 
Kajander K, and Korpela R. (2006). Clinical studies on alleviating the symptoms of 
irritable bowel syndrome with probiotic combination. Asia Pac. J. Clin. Nutri. 15, 576-
580. 
 
The authors screened for optimal strains, and developed a multi-species probiotic 
combination consisting of LGG and several other probiotic microorganisms. A 
randomised, double-blinded, placebo-controlled, six-month trial was used to study 
the therapeutic value of the probiotic combination in IBS patients. The authors found 
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that the multispecies probiotic combination, including LGG, seemed to alleviate IBS 
symptoms significantly.   
Comments: This is an interesting paper. However the age distribution of the patients 
is not clear, and the authors have not indicated whether any of the individuals with 
IBS included in the study were children.    
 
Wenus C, Goll R, Loken EB, Biong AS, Halvorsen DS, Florholmen J. (2007). 
Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur 
J.Clin. Nutr. 
   
87 eligible patients (selected from 853) were randomly divided into two groups (46 
test patients and 41 controls) and participated in a double-blind, placebo-controlled 
study. 8 patients (27.6%) in the control group and 2 (5.9%) in the test group 
experienced AAD. The study group was given 250mL Biola Surmelk per day, which 
contained LGG, L. acidophilus LA5, and Bifidobacterium Bb12. The aetiolgoical 
agents of the AAD were not identified, but one patient had Clostridium difficile and 
another had Yersinia enterocolitica. The authors rightly concluded that the results 
were promising, but that the study should be repeated with a larger group. They cited 
that the use of multistrain probiotics has been recommended, and also that they are 
more efficient when ingested as a fermented milk product, rather than as a freeze-
dried powder. 
 
Katz JA. (2006). Probiotics for the prevention of antibiotic-associated diarrhea and 
Clostridium difficile diarrhea. J.  Clin. Gastroenterol. 40:249-55 
 
This is a comprehensive review, published in 2006, and submitted for publication 
Sept. 2005. It has 54 references, of which 55% are from 2000 or later. The author is 
considered to be eminent in the field of gastroenterology and probiotics. The 
conclusions were as follows: 
Probiotics for prevention/treatment of C. difficile diarrhoea: 
A recent systematic review of the literature suggested that studies published to date 
provide insufficient evidence for the routine clinical use of probiotics to prevent or 
treat C. difficile diarrhoea. 
Probiotics in antibiotic-associated diarrhoea: The final verdict on the role of probiotics 
in antibiotic-associated diarrhoea awaits further large, well-designed, and well-
executed clinical trials, including dose-range studies, comparative trials, and formal 
cost-benefit analysis. 
Comments: The review is a balanced and unbiased assessment of the problems 
associated with the use of probiotics for prevention of diarrhoea. 
 
Yli-Knuuttila H, Snäll J, Kai K, Meurman H. (2006). Colonization of Lactobacillus 
rhamnosus GG in the oral cavity. Oral Microbiol. Immunol. 21:129-131 
 
The aim of this study was to investigate whether LGG could “be detected in the oral 
cavity after discontinuation of a product prepared with this bacterium.”  Fifty-six 
volunteers consumed Gefilus R juice for 14 days and saliva samples were collected 
daily on MRS agar. LGG-like colonies were analysed and characterized by both 
classical methods and PCR. LGG was only detected temporarily and the authors 
concluded that “permanent colonization of LGG in the oral cavity is improbable”, 
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Comments: This is a short communication and details on selection, age, and gender 
of volunteers, daily amount of Gefilus consumed, duration of the study period etc, 
were not provided. Nevertheless, it seems reasonable to concur with the authors’ 
conclusion. 
 
Guiemonde M, Kalliomäki M, Isolauri E, and Salminen S. (2006). Probiotic 
intervention in neonates - will permanent colonisation ensue? J. Pediatric 
Gastroentol. Nutri. 42: 604-606.  
 
The purpose of the study was to assess whether LGG can be detected in the gut 
microbiota in an infant population beyond the period of administration of LGG. 128 
infants, whose mothers were given daily capsules containing 1x 1010 CFU of LGG 
(63 subjects) or placebo (65 subjects) for 4 weeks before delivery, participated in the 
study. After delivery, LGG or placebo was administered either directly to the infant (in 
38 cases receiving LGG) or to the breast-feeding mother (25 cases receiving LGG) 
for 6 months. Faecal samples were collected at 6 and 12 months of age. In addition, 
the infants with samples positive for LGG at 12 months were also analysed at 24 
months. 
Results: 58% of the samples in the LGG treated group and 28% of the samples in the 
placebo group were positive for presence of LGG by colony identification after 6 
months (78% and 43% respectively by PCR). 
After 12 months, the occurrence of LGG was much less common, with 24% (treated 
group) and 14% (placebo group) positive by colony identification (26% and 20% 
respectively by PCR).  
Only two samples from individuals, who were positive at 12 months, were also 
positive at 24 months.  
Comments:  
A detailed description of materials and results were not presented in this “short 
communication”. The presence of LGG in infants in the placebo-group was high. This 
is probably because LGG was extensively used in Finland (where this study was 
conducted) during the study period. This confounder was not discussed in relation to 
the treated group. The term “colonisation” was not defined. The high presence of 
LGG in faeces at the first sampling occasion does not necessarily indicate high 
“colonisation”-rate in infants, since this sampling was immediately after the 
termination of the LGG administration period. The study demonstrated that LGG 
does not permanently colonise the intestine of infants. 
 
Petschaw P, Figueroa R, Harris CL, Beck LB, Ziegler E, Goldin B. (2005). 
Effects of feeding an infant formula containing Lactobacillus GG on the colonization 
of the intestine. J. Gastroenterol. 39: 786-790. 
 
This publication describes a multicentre, double-blind, randomised, parallel group 
study comprised of 3 study periods: a 7-day baseline period, during which all infants 
received the baseline/control formula; a 14-day test period, during which eligible 
infants were randomised and received either the control formula or 1 of the 3 
supplemented study formulas containing LGG at 3 different concentrations (low, 
medium, and high); a 14-day follow-up period, during which all infants received the 
baseline/control formula. The purpose of the study was to determine whether feeding 
LGG at varying concentrations (108 to 1010 cfu / day) would result in colonisation, 
defined as ≥ 1,000 cfu per gram of stool in 3 of the 5 samples collected during the 
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feeding period. Median stool counts of LGG (Log10 cfu/g) in colonised infants were 
5.24 (low), 6.05 (medium), and 5.97 (high). LGG was detected in stool samples for 
between 7 to 14 days after discontinuing LGG. 
Comments: This was a well-designed study, intended to determine whether feeding 
LGG at varying concentrations affected the “colonisation” of the infants’ intestines. 
The results obtained are similar to those previously reported by others. The limited 
number of participants (n=55) and the short study period (4 weeks) mean that it is not 
possible to draw any firm conclusions. Although colonisation is probably not an 
appropriate term to use for LGG, some survive passage through the gastrointestinal 
tract.  
 
Bier DM, Doyle MP, Borzelleca JF, Kolezko B, Clemens RA, O’Sullivan DJ. 
(2006). Conclusions of the expert panel: Generally Regarded as Safe (GRAS)-
Determination for the use of Lactobacillus casei spp. rhamnosus strain GG in exempt 
infant formula. Prepared for Mead Johnson Nutritionals-Evansvielle-Indiana. 
 
Members of the expert group evaluated the available publicity information on the 
proposed use of LGG in exempt infant formula. The evaluation included a review of 
the starting materials, production methods, and genetic stability of the LGG; the 
effects of LGG on the gastrointestinal and immune systems; the history of apparent 
safe use of lactic acid bacteria, the genus Lactobacillus, and the specific strain LGG; 
and the apparent safety of administering LGG to newborn infants. The expert group 
concluded that the powder containing Lactobacillus casei spp. rhamnosus strain GG, 
manufactured by Valio Ltd., could be generally regarded as safe (GRAS) by scientific 
procedure, for use under the supervision of a physician as a source of a LGG in 
formula intended for term infants from time of birth. 
Comments: The phrase that “LGG appears to confer possible beneficial effects with 
respect to allergic symptoms” does not concur with the published data that claim 
beneficial effects on allergic symptoms (Kalliomaki et al., 2001; Kalliomaki et al., 
2003). The term “possible” suggests that the expert group was not wholly confident 
with the published articles regarding beneficial effects on allergic symptoms.  
The expert group did not confirm the colonisation of LGG on the intestinal surface, 
which has been published several times, but used the phrase “can adhere to 
intestinal surfaces”.  
According to the expert group LGG may inhibit translocation of intestinal pathogens, 
and translocation of LGG itself has been only rarely observed in controlled studies. 
The expert group suggested use of LGG under supervision of a physician from time 
of birth.  Many infants with impaired immunocompetence, heart defects, or central 
lines are probably not identified at birth.    
 
 
Land MH, Rouster-Stevnes K, Woods CR, Cannon ML, Conta J, Shetyy KS. 
(2005). Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115: 178-
181. 
This paper reports on 2 patients who received Lactobacillus LGG and subsequently 
developed bacteraemia and sepsis attributable to the LGG. DNA-fingerprinting 
revealed that the implicated LGG strain was similar to the probiotic strain ingested by 
the patients. Both patients were children (one aged 6-weeks, the other aged 6-
years). The first patient had been admitted for scheduled repair of a double-outlet 
right ventricle and pulmonis stenosis. The other patient, who had cerebral palsy, 
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microcephaly, mental retardation, and a seizure disorder that required feeding 
through a gastrojejunostomy tube, had been admitted for treatment of a urinary tract 
infection.   
Comments: This report confirms that LGG can cause invasive disease in certain 
individuals. 
 
Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. (2007). Soluble 
protein produced by probiotic bacteria regulate intestinal epithelial cell survival and 
growth. Gastroenterology. 132: 562-575. 
 
Two novel proteins (75 and 40 kD) secreted by LGG were purified and characterized 
and shown to prevent cytokine-induced apoptosis in human and mouse epithelial 
cells. Polyclonal antibodies against these proteins were used to prepare LGG culture 
media depleted of these proteins (= control). The proteins were shown to activate Akt 
(which inhibits apoptotic processes), inhibit cytokine-induced epithelial cell apoptosis, 
and promote cell growth in human and mouse colon epithelial cells and cultured 
mouse colon explants. The proteins also significantly reduced damage to the colon 
epithelium by tumour necrosis factor (TNF). A weak reaction with the antisera to p75 
was also found with the supernatant from another Lactobacillus strain (three other 
strains were investigated, two L. casei and one L. acidophilus). There was also a 
relationship between p40 from LGG and from a strain of L. casei. 
The authors proposed that supernatant-derived proteins from LGG could be used to 
regulate intestinal inflammatory responses. LGG has been shown to induce 
remission and prevent recurrence of IBD in patients and animals. However this effect 
was not shown in a trial with children with Crohn’s disease. The authors also noted 
concerns regarding treating the very young, following the cases of bacteraemia 
associated with probiotic therapy (Land et al, 2005). They therefore suggested that 
the use of bacteria-derived proteins could be an alternative for treatment of IBD and 
other inflammation-derived disorders. Reference is made to communication between 
intestinal flora and epithelial cells; apparently some probiotic strains need direct cell 
contact with the epithelium in order for an effect to occur, whereas the strain 
investigated here (LGG) has an active secreted protein.  
 
 
Zhang L, Li N, des Robert C, Fang M, Liboni K, McMahon R, Caicedo RA, Neu J. 
(2006). Lactobacillus rhamnosus GG decreases lipopolysaccharide-induced systemic 
inflammation in a gastronomy-fed infant rat model. J. Pediatr. Gastroenterol. Nutr. 42: 
545-552. 
 
Two groups of rat pups (6-7 day old) were fed a rat milk substitute combined with E. 
coli lipopolysaccharide (LPS). One group was also given a supplement of LGG 
(108cfu/L milk). Mother-fed rat pups were used as control.  
Mother-fed pups grew better than the pups on substitute diet, and in this respect the 
two experimental groups did not differ. However, the experimental group without 
LGG showed striking metaplasia of the villous epithelium, which was absent in the 
mother-fed pups and was attenuated in the LGG-supplemented pups. Assay of 
markers of inflammation (CINC-1, TNF-α, MPO and cytokine multiplex assay) 
showed that supplementation of the milk with LGG markedly reduced the 
inflammatory response to LPS, although the response was higher than in the control 
group. LGG had therefore attenuated or reduced the response, but did not totally 
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abrogate it. The authors proposed potential mechanisms for the observed effects and 
suggested that these results may be of importance for the treatment of critically 
underweight infants, who may suffer from systemic infections which may result in 
systemic inflammation, leading to necrotizing conditions. Should this state occur in 
the intestine, the inflammatory response can cause damage in distal organs? Various 
articles are cited reporting studies on anti-inflammatory actions of other probiotics.  
This article provides new information about effects of LGG – in rats. 
This study was funded by Mead Johnson.  
 
Apostolou E, Pelto L, Kirjavainen PV, Isolauri E, Salminen SJ, Gibson GR. 
(2001).  Differences in the gut bacterial flora of healthy and milk-hypersensitive 
adults, as measured by in situ hybridization. FEMS Immunol. Med, Microbiol. 30:217-
221.   
 
Predominant gut flora (genera) were determined in two groups of adults (9 healthy 
and 8 milk-hypersensitive) both before and after 4 weeks of LGG intervention. It was 
concluded that the gut flora in both groups were similar and that intervention with 
LGG resulted in an increase in Bifiobacteria in healthy, but not milk-hypersensitive, 
adults. Pathogenic types were not reduced by LGG intervention. These results 
therefore indicate that the gross gut flora is not directly associated with milk 
hypersensitivity. 
Comments: The number of participants in this study was low, and calculations based 
on the results show that it would be necessary to have between 70 and 200 
individuals per group.  The bacteria genera were identified by the use of 4 
oligonucleotide probes. Considering the enormous variation of the gut flora, this is a 
very coarse study. In addition the bacteria were detected in faecal samples, which 
may not be representative of the flora in the small and large intestine. The authors 
concluded that intervention with LGG does not down-regulate the milk induced 
inflammatory response by altering the microbial gut flora. It is questionable whether 
this proposition is valid, given the small size of the study. This study was published 6 
years ago; as the pace of development in this field is rapid, this study can be 
considered old. 
 
Roselli M, Finamore A, Britti MS, Mengheri E.  (2006). Probiotic bacteria 
Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal 
Caco-2 cells from the inflammation response induced by enterotoxinogenic 
Escherichia coli K88. Br. J. Nutr. 95:1177-1184. 
 
Two probiotic strains, LGG and MB5, were investigated for their ability to prevent 
adhesion of E. coli K88 in vitro. Numbers of adhering EC appeared to be affected by 
the numbers of MB5 added, but were not number-dependent with respect to LGG. 
When spent supernatant was added, this also reduced the adhesion. Supernatant 
treated with proteolytic enzymes had the same effect, indicating that the soluble 
active component was not a protein. It was suggested that the effect could be due to 
competition for binding sites. Both the strains studied (when living, not when dead) 
also reduced neutrophil migration induced by K88, and the supernatant also had this 
effect. LGG, but not MB5, induced IL-1ß indicating variation in action of different 
probiotic strains. The authors rightly suggested that in vivo studies must be 
conducted before either MB5 or GG can be suggested as being of use in the 
prevention or alleviation of ETEC-induced intestinal disorders. 
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Vendt N, Grünberg H, Tuure T, Malminiemi O, Wuoolijoki E, Tillmann V, Sepp E, 
Korpela R. (2006). Growth during the first 6 month of life in infants using formula 
enriched with Lactobacillus rhamnosus GG: double-blind, randomized trial. J. Hum. 
Nutr. Dietet. 19:51-58. 
 
This is a prospective, randomised, double-blind, placebo-controlled clinical study 
conducted in Tartu, Estonia. A cohort of 120 healthy, full-term children aged between 
0 and 2 months, and on formula for at least half their daily feeding, participated. The 
formula that had been given seemed to be Tutteli ®.  When enrolled, the infants were 
randomised into two group, one of which continued on the same unchanged formula, 
whilst the other received the same formula, to which had been added L. rhamnosus 
(at the end of shelf life of formula, the concentration of bacteria was claimed to be log 
7 CFU per gram). 105 of the participating infants completed the study. 
Findings: Slight, but not statistically significant, increases in the LGG group were 
reported for the following parameters: defecation frequency, number of loose stools, 
infectious periods, and crying behaviour.  Growth rates (increase in length and 
weight) were approximately the same in both groups. The authors claimed that 
“infants fed with LGG-enriched formula grew better than those fed with regular 
formula”. However, this claim is based upon a calculation based on “data of normal 
Estonian infants” and no reference to this material is provided. 
Comments: Many of the points raised by the authors in this publication are 
controversial. 
 
Rinne M, Kalliomäki M, Salminen S, Isolauri E. (2006). Probiotic intervention in the 
first months of life: short-term effects on gastrointestinal symptoms and long-term 
effects on gut microbiota. J. Pediatr, Gastroent. Nutr.43:200-205 
 
This is a double-blind, placebo-controlled trial, following a protocol published some 
years ago by the same group of investigators. It may be reasonable to assume that 
the cohort described in this paper, is a part of the cohort previously described. 
The aim of this study was to investigate whether administration of LGG affected 
particular selected symptoms and signs in the infants at 7 and 12 weeks old, and the 
composition of a defined part of the gut microbiota at 6, 12, 18, and 24 months of 
age. 
In total, for the data obtained at 7 and 12 weeks of age, the values given for vomiting, 
loose stools, watery stools, crying and fussing were higher in the group that received 
LGG than in the group that received placebo. However, at both time points the 
differences were small.  The authors concluded that LGG “was well tolerated”. Based 
upon these data, it might have been more appropriate to state that LGG did not 
cause any major harm.  
Further, the authors concluded that LGG “did not significantly interfere with long-term 
composition or quantity of gut microbiota”. In considering these data it should be 
noted that over 20% of the faecal samples were missing (113 out of 528) and that 
only a minor proportion (at least at 18 and 24 months of age) was investigated. 
 
Rinne M, Kalliomaki M, Arvlommi H, Salminen S, Isolauri M. (2005). Effect of 
probiotics and breasfeeding on the bifidobacterium and Lactobacillus / Enterococcus 
microbiota and humoral immune responses. J. Pediatr. 147: 186-191. 
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This is a double blind, placebo-controlled trial; apparently following a protocol 
published 6 years ago by the same group of investigators, and presumably using the 
same group of subjects as described in previous papers. 
The aim of this part of the study was to assess the impact of probiotics and 
breastfeeding on gut microbiota composition, as characterised by bifidobacteria and 
lactobacilli/enterococci, and humoral immune response as indirectly assessed by 
circulating immunglobulin-secreting cells. Additionally, it was intended to investigate 
the impact of sCD14 in colostrum. 
The impact of sCD14 is somewhat difficult to evaluate in this paper. The authors 
claimed that “again, the CD14 in colostrums correlated with number of IgM and IgA 
cells; P=0.05 on both”. However, colostrum was investigated in less than 50% of the 
mothers, and the relative distribution between two groups is not given.  
If the data collected at 3 and 6 months of age are considered together, the number of 
IgA, IgG, and IgM cells were higher in the group receiving LGG than in the group 
receiving placebo at two out 6 measurement points. However, at all points, the 
differences were small. At 12 months of age, the number was higher in the group 
receiving LGG. The authors found a correlation between duration of breastfeeding 
and number of immunglobulin-secreting cells and claimed that “The results presented 
here suggest that some human-derived compounds may be mandatory for probiotics 
to stimulate humoral immune response ….” If this statement is accepted, then the 
effect of probiotics in infants should be properly investigated.  
Taken together, the data from 3, 6, and 12 months of age, the number of 
bifidobacteria and lactobacilli/enterococcus were lower at 5 out of 6 measurement 
points in the group receiving LGG than in the group receiving placebo. The effect of 
breastfeeding on the presence of bifidobacteria at 3 and 6 months of age was clearly 
shown. 
Conclusion: the results reinforce current knowledge on the impact of breastfeeding 
upon composition of the microbiota and development on Ig-secreting cells in infants.               
 
Maija-Liisa Saxelin. Note Dated 31.3.2005. Enzyme activities of Lactobacillus GG 
with particular emphasis on beta-glucuronidase 
This is not a scientific report or article, but provides useful information regarding the 
strain. 
 
APIZYM profile
The profile is provided for LGG and L.rhamnosus type strain (type strain), and the 
values are relatively similar. 
          
Valio. (2005). Safety of LGG administration for infants and children in controlled 
clinical studies.  
This is not a scientific report or article, but a list of published articles, in which LGG 
has been administered to infants and young children in clinical and human 
intervention studies. It is claimed that none of these studies report the occurrence of 
any adverse effects.     
 
Valio. (2004). Identification of Lactobacillus GG  
Valio. (2003). Lactobacillus GG- qualification analysis.  
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These two attachments are not scientific reports or articles, but provide useful 
information regarding the strain, genetic and biochemical properties, antimicrobial 
susceptibility, etc.    
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